PPRI
Pharmaceutical Pricing and Reimbursement Information

REPUBLIC OF TÜRKİYE
MINISTRY OF HEALTH
MEDICINES AND MEDICAL DEVICES AGENCY OF TÜRKİYE

SGK
SOSYAL GÜVENLİK KURUMU

Türkiye

Recent and planned developments in pharmaceutical policies 2026

CHANGES IN PRICING

[13/03/2026]: Introduction of a **price reduction model linked to generic market entry**. **phased price reduction mechanism for reference products** following the market entry of the first equivalent product.
Previously, prices were reduced to 60%; under the new system:
- 80% in Year 1
- 75% in Year 2
- 70% in Year 3

The implementation starts within six months of the marketing authorisation date. Market-based adjustments apply if domestically manufactured equivalents reach defined market share thresholds.

[01/04/2026]: Increase in the reference pricing exchange rate (EUR/TRY) from 60% to 65% of the previous year's average euro value.

[01/04/2026]: Increase in regressive remuneration margins applied to wholesale and pharmacy retail prices according to the exchange rate.

VAT on medicines: No changes.

Planned: Preparatory work ongoing for **value-based pricing methodologies and procedures**.

CHANGES IN REIMBURSEMENT

Reimbursement lists: Positive list system remains in place (no negative list).

[17/04/2026]: Number of reimbursed medicines increased to **8,559**.

[08/04/2026]: Named Patient Programme: 415 medicines covered.

[01/01/2026]: Increase in prescription co-payments (fees):
- TRY 3.76 for up to 3 boxes
- TRY 1.25 for each additional box

[27/11/2025]: Change in internal reference pricing (generic grouping): Reimbursement limit increased from **5% to 6% above the lowest-priced product** in the group; any excess is subject to co-payment.

Reimbursement reviews: No changes.

Assessment/appraisal (HTA): No major changes.

Other changes: No structural changes in decision-making processes or committees.

OTHER CHANGES

Generic/biosimilar policies: No changes.

Volume control / prescribing measures: No changes.

Medicines shortages [10/2025]: The PREDIS system (an AI-based early warning system) enables ongoing monitoring, real-time tracking of availability, anomaly detection, and short-term forecasting, thereby supporting proactive shortage management.

Educational and information activities (e.g. targeted at health professionals and/or patients, e.g. on antibiotic use /AMR, generics and biosimilars), stakeholder dialogues: Routine training, awareness activities for healthcare professionals and stakeholder dialogues continue.

IT / Real-world data [01/2026]: A pilot data collection initiative is being implemented within the Ministry of Health to generate real-world evidence (RWE) on high-cost medicines under the Named Patient Programme, focusing on effectiveness and safety outcomes.

SPECIAL TOPIC:
Regulation, pricing and reimbursement of pharmaceutical combination products

Definition

- A medicinal product is defined as a substance or combination of substances intended for treating or preventing disease, or for restoring, correcting or modifying physiological functions through pharmacological, immunological or metabolic action.

Regulation

- Fixed-dose combinations are regulated under national marketing authorisation legislation. Applications must demonstrate quality, safety and efficacy of the combination. For known active substances used together, bioavailability/bioequivalence data and supporting literature are required.
- Where active substances have not been previously used in combination, clinical (and where necessary pre-clinical) studies must be provided.

Pricing

- Combination products are priced in line with general pricing rules (imported/domestically manufactured status and external reference pricing). Pricing may take into account reference products corresponding to individual active substances.

Reimbursement

- A cost-containment approach is applied: Reimbursement levels for combination products should not exceed the total cost of the lowest-priced equivalents of the corresponding mono-components, adjusted for adjusted for strength, pharmaceutical form and pack size.